# Telomir Pharmaceuticals, Inc.: overview TELO · Nasdaq · CIK 1971532 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/telo.md) · [Financials](/companies/telo/financials.md) · [Filings](/companies/telo/filings.md) · [Insiders](/companies/telo/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.20)](/filings/0001493152-25-021496.md) | not reported | [(0.07)](/filings/0001493152-26-023010.md) | [(0.17)](/filings/0001493152-26-037854.md) | [(0.03)](/filings/0001493152-25-021496.md) | not reported | [(0.03)](/filings/0001493152-26-023010.md) | [(0.79)](/filings/0001493152-26-037854.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.03)](/filings/0001493152-24-012049.md) | [0.48](/filings/0001493152-25-004872.md) | [(0.56)](/filings/0001493152-26-010625.md) | [(0.33)](/filings/0001493152-26-010625.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL not reported. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/telo/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.1m | 1,613,639 | | Added +618,266 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $433.9k | 338,875 | | Added +89,789 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $359.0k | 280,472 | | Reduced −8,726 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $288.4k | 225,304 | | Added +89,763 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $78.8k | 61,532 | | Added +19,688 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $75.0k | 58,600 | | Unchanged | | [Bank of New York Mellon Corp](/funds/1390777.md) | 2026-06-30 | $65.9k | 51,454 | | Unchanged | | [CAPTRUST FINANCIAL ADVISORS](/funds/1512024.md) | 2026-06-30 | $65.5k | 51,194 | | New +51,194 | | [OSAIC HOLDINGS, INC.](/funds/1677044.md) | 2026-06-30 | $53.1k | 41,490 | | Added +5,695 | | [World Investment Advisors](/funds/1652594.md) | 2026-06-30 | $48.1k | 37,037 | | Unchanged | ## Recent filings [All 145 filings](/companies/telo/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-06 | 08:00 ET | [8-K](/filings/0001493152-26-045860.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-045860 | | 2026-09-17 | 08:30 ET | [8-K](/filings/0001493152-26-043053.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-043053 | | 2026-09-16 | 16:30 ET | [8-K](/filings/0001493152-26-042926.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-042926 | | 2026-09-14 | 08:00 ET | [8-K](/filings/0001493152-26-042483.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-042483 | | 2026-08-13 | 17:10 ET | [10-Q](/filings/0001493152-26-037854.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037854 | | 2026-08-10 | 08:00 ET | [8-K](/filings/0001493152-26-036742.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-036742 | | 2026-07-28 | 17:00 ET | [DEF 14A](/filings/0001493152-26-035026.md) | Proxy statement, period 2026-07-28 | 0001493152-26-035026 | | 2026-06-15 | 08:00 ET | [8-K](/filings/0001493152-26-028614.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-028614 | | 2026-06-08 | 17:00 ET | [8-K](/filings/0001493152-26-027752.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-027752 | | 2026-05-20 | 08:00 ET | [8-K](/filings/0001493152-26-024517.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-024517 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-010625.md), filed Mar 17, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1971532 - Tickers: TELO - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: FL - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 16:31 ET. No prices; not investment advice.